CARTISTEM
MarketedAn allogeneic cord-blood-derived stem cell therapy for cartilage regeneration in knee osteoarthritis, with real-world data from about 560 patients in Korea.
FROM PUBLIC EVENTS · 2026-11-18
Global approvals · expansion Has completed a Phase 3 trial in Japan for CARTISTEM, already used in Korea, and started dosing in a US Phase 3 trial.
Roles often seen at this stageClinical & PV · Regulatory affairs · Manufacturing & MSAT
A biotech company behind the cord-blood-derived stem cell therapy CARTISTEM and the Celltree cord blood bank, which has stored samples for more than 340,000 people.
An allogeneic cord-blood-derived stem cell therapy for cartilage regeneration in knee osteoarthritis, with real-world data from about 560 patients in Korea.
A Phase 3 trial in 130 patients at 13 Japanese sites met its primary endpoints; Teikoku Pharma holds exclusive distribution rights in Japan.
A single pivotal Phase 3 trial in 300 patients at about 70 sites in the US and Canada, with first dosing in July 2026.
Cord blood bank with more than 340,000 people stored; the company has also begun storing umbilical cord tissue, fat and immune cells.
Enrolled and dosed the first patient in the US Phase 3 trial of CARTISTEM.
Announced that the Japanese Phase 3 trial of CARTISTEM met its primary endpoints.
Launched storage services for umbilical cord tissue, fat and immune cells.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.